Biofrontera

Company BFRI

Last mentioned: Mar 19, 2026

Timeline

  1. Q4 2025 Earnings

    Both companies report year-end results showing strong commercial momentum and narrowing losses.

  2. Major Health Plan Contract

    DarioHealth signs a multi-year agreement with a top-five national US health insurer.

  3. Biofrontera Supply Chain Update

    Resolution of RhodoLED manufacturing bottlenecks, enabling faster lamp deployment.

  4. DarioHealth MSK Launch

    Full integration of musculoskeletal health modules into the core digital platform.

Stories mentioning Biofrontera 1

market-trends Neutral

Biofrontera and DarioHealth Q4 Results Signal Shift Toward Commercial Scaling

Biofrontera and DarioHealth reported Q4 2025 earnings, highlighting a pivotal transition from clinical development to aggressive commercial scaling. While Biofrontera capitalizes on its dermatology market share with Ameluz, DarioHealth is demonstrating the viability of its multi-condition digital health platform through expanded B2B partnerships.

2 sources